LitAlert ~~ GeneLit.com

    • Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer: A Secondary Analysis of the GeparOcto Randomized Clinical Trial.
    • Pohl-Rescigno E, Hauke J, Loibl S, Möbus V, Denkert C, Fasching PA, Kayali M, Ernst C, Weber-Lassalle N, Hanusch C, Tesch H, Müller V, Altmüller J, Thiele H, Untch M, Lübbe K, Nürnberg P, Rhiem K, Furlanetto J, Lederer B, Jackisch C, Nekljudova V, Schmutzler RK, Schneeweiss A, Hahnen E.
    • JAMA Oncol. 2020 Mar 12. doi: 10.1001/jamaoncol.2020.0007. [Epub ahead of print]
    • The Ethics of Delivering Precision Medicine-Pretest Counseling and Somatic Genomic Testing.
    • Borno HT, Rider JR, Gunn CM.
    • JAMA Oncol. 2020 Mar 12. doi: 10.1001/jamaoncol.2020.0016. [Epub ahead of print]
    • Commentary
    • Prevalence of Pathogenic Variants in Cancer Susceptibility Genes Among Women With Postmenopausal Breast Cancer.
    • Kurian AW, Bernhisel R, Larson K, Caswell-Jin JL, Shadyab AH, Ochs-Balcom H, Stefanick ML.
    • JAMA. 2020 Mar 10;323(10):995-997. doi: 10.1001/jama.2020.0229.

    Press: Inherited Mutations in Postmenopausal Breast Cancer Patients Suggest Genetic Testing Is Warranted. (GenomeWeb)

    • Use of an Online Breast Cancer Risk Assessment and Patient Decision Aid in Primary Care Practices.
    • Eden KB, Ivlev I, Bensching KL, Franta G, Hersh AR, Case J, Fu R, Nelson HD.
    • J Womens Health (Larchmt). 2020 Mar 10. doi: 10.1089/jwh.2019.8143. [Epub ahead of print]
    • How and when to refer patients for oncogenetic counseling in the era of PARP inhibitors.
    • Neviere Z, De La Motte Rouge T, Floquet A, Johnson A, Berthet P, Joly F.
    • Ther Adv Med Oncol. 2020 Feb 28;12:1758835919897530. doi: 10.1177/1758835919897530. eCollection 2020.